NCT05501054 2026-01-14Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.M.D. Anderson Cancer CenterPhase 1/2 Active not recruiting50 enrolled